
Opinion|Videos|May 2, 2025
Understanding OS Through 2 Lenses: Patients and Providers in EGFRm NSCLC
Panelists discuss how health care providers and patients view survival differently, with providers being more data driven and patients focusing on living with minimal symptoms and maintaining quality of life.
Advertisement
Episodes in this series

Patient vs Health Care Provider Perspectives on Treatment Goals
Main Discussion Topics:
- Differences between how patients and providers view survival benefits
- Patient priorities regarding quality of life and symptom management
- Challenges in communicating complex efficacy data to newly diagnosed patients
Key Points for Physicians:
- Health care providers tend to be more data driven in their approach
- Patients often prioritize living with minimal symptoms and maintaining normalcy
- Newly diagnosed patients may be overwhelmed and unable to process statistical benefits
Notable Insights:
There is an emotional component to treatment decision-making that physicians must navigate, particularly when patients are still processing their diagnosis.
Clinical Significance:
Effective communication with patients requires understanding their priorities and emotional state, moving beyond statistical data to address their specific concerns and goals.
Advertisement
Related to this article

Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.

Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.

Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.

Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.

An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5

